We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
- Authors
Wilgenhof, Sofie; Du Four, Stephanie; Everaert, Hendrik; Neyns, Bart
- Abstract
Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. The durable clinical benefit seen in these patients despite the observed atypical response patterns highlights the necessity for comprehensive clinical decision making.
- Publication
Cancer investigation, 2012, Vol 30, Issue 10, p712
- ISSN
1532-4192
- Publication type
Journal Article
- DOI
10.3109/07357907.2012.727934